Literature DB >> 7599068

An evaluation of hepatic extraction and clearance of doxorubicin.

D A August1, N Verma, M A Vaertan, R Shah, D E Brenner.   

Abstract

A swine model was developed to study quantitatively the pharmacokinetics of hepatic extraction and clearance of doxorubicin (DOX). Systemic and hepatic artery infusions of DOX (0.5-9 mg kg-1) were administered to 34 pigs. Pharmacokinetic analysis was simplified by use of a double-balloon catheter in the inferior vena cava to collect hepatic venous effluent. During hepatic artery infusion only, DOX in hepatic venous blood was extracted using activated carbon filters to prevent drug recirculation. Hepatic extraction and clearance of DOX were independent of dose and route of administration. Extraction ratios varied from 0.75 to 0.91 during hepatic artery infusion and from 0.50 to 0.72 during systemic infusion. Clearance results were analogous. After cessation of drug infusions, hepatic extraction and clearance of DOX was negative, suggesting that the liver serves as a drug reservoir during DOX infusion and subsequently is a net source of unmetabolised drug. Liver extraction and clearance of DOX in pigs are substantial. During either systemic or hepatic artery infusion of DOX, the liver serves as a drug reservoir. Subsequent mobilisation of this hepatic pool of DOX may cause prolonged systemic exposure to drug.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599068      PMCID: PMC2034109          DOI: 10.1038/bjc.1995.278

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  Distribution and metabolism of adriamycin in mice. Comparison with daunomycin.

Authors:  G Di Fronzo; R A Gambetta; L Lenaz
Journal:  Rev Eur Etud Clin Biol       Date:  1971 Jun-Jul

3.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee; H Kon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

4.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  G Pelletier; A Roche; O Ink; M L Anciaux; S Derhy; P Rougier; C Lenoir; P Attali; J P Etienne
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

5.  Hepatic extraction of adriamycin in patients with hepatocellular carcinoma.

Authors:  F Ballet; J C Barbare; R Poupon
Journal:  Eur J Cancer Clin Oncol       Date:  1984-06

6.  Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl.

Authors:  S Gelman; E Dillard; E L Bradley
Journal:  Anesth Analg       Date:  1987-10       Impact factor: 5.108

7.  Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia.

Authors:  D E Brenner; P H Wiernik; M Wesley; N R Bachur
Journal:  Cancer       Date:  1984-03-01       Impact factor: 6.860

8.  Effect of allyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit.

Authors:  D E Brenner; L B Anthony; S Halter; N L Harris; J C Collins; K R Hande
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

9.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

Authors:  P Ruszniewski; P Rougier; A Roche; P Legmann; A Sibert; S Hochlaf; M Ychou; M Mignon
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

10.  Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity.

Authors:  P L Gutiérrez; M V Gee; N R Bachur
Journal:  Arch Biochem Biophys       Date:  1983-05       Impact factor: 4.013

View more
  6 in total

1.  Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity.

Authors:  Ashley J Smuder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-08-28       Impact factor: 3.619

2.  Serum biomolecules unable to compete with drug refilling into cyclodextrin polymers regardless of the form.

Authors:  Nathan A Rohner; Alan B Dogan; Olivia A Robida; Horst A von Recum
Journal:  J Mater Chem B       Date:  2019-09-11       Impact factor: 6.331

3.  Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model.

Authors:  Christine E Swenson; Dieter Haemmerich; Donald H Maul; Bridget Knox; Nicole Ehrhart; Robert A Reed
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

4.  DPPG2-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer.

Authors:  F Johannes P van Valenberg; Iris S G Brummelhuis; Lars H Lindner; Felix Kuhnle; Barbara Wedmann; Pascal Schweizer; Martin Hossann; J Alfred Witjes; Egbert Oosterwijk
Journal:  Int J Nanomedicine       Date:  2021-01-07

Review 5.  Consideration of Sex as a Biological Variable in the Development of Doxorubicin Myotoxicity and the Efficacy of Exercise as a Therapeutic Intervention.

Authors:  Ryan N Montalvo; Vivian Doerr; Branden L Nguyen; Rachel C Kelley; Ashley J Smuder
Journal:  Antioxidants (Basel)       Date:  2021-02-25

6.  Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities.

Authors:  Anjan Motamarry; A Marissa Wolfe; Krishna K Ramajayam; Sanket Pattanaik; Thomas Benton; Yuri Peterson; Pegah Faridi; Punit Prakash; Katherine Twombley; Dieter Haemmerich
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.